Benzodioxoles
"Benzodioxoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds based on benzene fused to oxole. They can be formed from methylated CATECHOLS such as EUGENOL.
Descriptor ID |
D052117
|
MeSH Number(s) |
D03.383.246.118 D03.633.100.115
|
Concept/Terms |
Benzodioxoles- Benzodioxoles
- 1,3-Dioxindans
- 1,3 Dioxindans
- Methylenedioxybenzenes
- 1,3-Dioxaindans
- 1,3 Dioxaindans
|
Below are MeSH descriptors whose meaning is more general than "Benzodioxoles".
Below are MeSH descriptors whose meaning is more specific than "Benzodioxoles".
This graph shows the total number of publications written about "Benzodioxoles" by people in this website by year, and whether "Benzodioxoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 2 | 0 | 2 | 2010 | 1 | 1 | 2 | 2011 | 0 | 1 | 1 | 2012 | 2 | 0 | 2 | 2015 | 1 | 0 | 1 | 2016 | 1 | 0 | 1 | 2017 | 4 | 0 | 4 | 2018 | 3 | 1 | 4 | 2019 | 4 | 2 | 6 | 2020 | 3 | 1 | 4 | 2021 | 5 | 5 | 10 | 2022 | 0 | 8 | 8 | 2023 | 1 | 8 | 9 | 2024 | 4 | 4 | 8 | 2025 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzodioxoles" by people in Profiles.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
-
Wisniewski BL, Shrestha M, Bojja D, Shrestha CL, Lee CS, Ozuna H, Rayner RE, Bai S, Cormet-Boyaka E, Reynolds SD, Kopp BT. Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2025 Mar 01; 328(3):L324-L333.
-
O'Malley SS, Miranda R, Book SW, Chun TH, Liss T, Malcolm RJ, Muvvala SB, Padovano HT, Schacht JP, Blackburn B, Diamond I, Ransom J, Ryan ML, Falk DE, Litten RZ. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol Alcohol. 2025 Jan 19; 60(2).
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515.
-
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
-
Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024 Aug 08; 10(1):53.
-
Stewart KL, Szczesniak R, Liou TG. Predicting weight gain in patients with cystic fibrosis on triple combination modulator. Pediatr Pulmonol. 2024 Jun; 59(6):1724-1730.
-
Duong JT, Pope CE, Hayden HS, Miller C, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Hoffman LR, Narkewicz MR, Green N. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024 May; 23(3):490-498.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|